The Influence of Helminth Immune Regulation on COVID-19 Clinical Outcomes: Is it Beneficial or Detrimental?
,Muluneh Ademe,Friehiwot Girma
DOI: https://doi.org/10.2147/IDR.S335447
2021-10-27
Infection and Drug Resistance
Abstract:Muluneh Ademe, 1 Friehiwot Girma 2 1 Department of Microbiology, Immunology and Parasitology, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia; 2 Department of Pediatrics and Child Health Nursing, School of Health Sciences, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia Correspondence: Muluneh Ademe P.O. Box: 9086, Addis Ababa, Ethiopia Tel +251 912 63 4868 Fax +251 1 551 30 99 Email Immunologically, chronic worm infections prevent themselves from strong immune responses by skewing the host response towards a T helper 2 (Th2) type. The regulatory response initiated by helminth infections is supposed to temper responses to non-helminth antigens including viral infections which will, in turn, alter the clinical outcomes of infections. In view of this, recent reports highlighted the possible negative associations of severe COVID-19 and helminth co-infections in helminth-endemic regions. As the pathology of COVID-19 is primarily mediated by an excessive immune response and subsequent cytokine storm, which contributes to the poor prognosis of COVID-19, helminth-driven immune modulation will hypothetically contribute to the less severe outcomes of COVID-19. Nevertheless, emerging reports also stated that COVID-19 and helminth co-infections may have more hidden outcomes than predictable ones. Herein, the current knowledge on the interaction of COVID-19 and helminth co-infections will be discussed. Keywords: SARS-CoV-2, worm co-infections, cytokine storm, Th2 response COVID-19 becomes the most serious global public health crises in modern times. 1 However, the differences in the susceptibility to COVID-19 and the disease severity across nations continue to be a concern. Available reports showed that this new public health crisis has been most active in countries where helminth infections are rare. 2 Although the number of cases and deaths is on the rise, the morbidity and mortality of COVID-19 in low-income countries has been lower than predicted. 3,4 Data coming from the COVID-19 pandemics show that pre-existing chronic diseases might influence the clinical outcomes of COVID-19 infection. 5 In view of this, recent reports drew attention to the associations between chronic helminth infection and COVID-19 disease severity in helminth-endemic regions. Yet, reports vary considerably and there is no common understanding of the interaction between these two disease conditions. In different reports, the possible beneficial and detrimental effects of COVID-19 and helminth co-infections have been shown. The aim of this review is, therefore, to summarize the current understanding on the interaction of COVID-19 and helminth co-infections. The potential influence of helminth co-infections on the clinical outcome of COVID-19 patients will be discussed. For this purpose, peer-reviewed research articles, reviews and short communications by international organizations were reviewed. Search engines including PubMed Central, Scopus, and Google Scholar were used. In the search engines, we have used key words (phrases) including but not limited to COVID-19, Helminth infections, Immunomodulation, Immunopathology, Epidemiology, Interaction, and Clinical outcome. The search was restricted to English language. Coronavirus disease 2019 (COVID-19) is caused by the novel betacoronavirus, now named severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). 6,7 According to the phylogenetic diversity studies, SARS-Cov-2 and SARS-Cov share about 80% nucleotide sequence. SARS-Cov had been a cause of an epidemic in 2002/3 which affected 26 countries with about 8000 cases. 8 The first COVID-19 cases have been reported from the Chinese city of Wuhan by the end of 2019. Since then, cases have started to be reported in different countries, and the disease was declared a pandemic by WHO in March 2020. COVID-19 has currently affected more than 216 countries with over 200 million cases. 9,10 Indeed, the overall burden of COVID-19 might be higher than the reported case counts because only a fraction of infections is diagnosed and reported. In Europe and the United States (US), for instance, seroprevalence surveys have shown that the rate of prior exposure to SARS-CoV-2 exceeds the incidence of reported cases by approximately 10-fold or more. 11,12 The highest numbers of cases and deaths have been reported from the USA, Brazil, and India, however, Africa has a low number of COVID-19 cases and fatalities compared to other continents partly be due to limited testing capacity and delays in reporting confirmed cases. 13,14 The sign and symptoms of COVID-19 vary from person to person. 13 However, pneumonia and acute respiratory distress s -Abstract Truncated-
pharmacology & pharmacy,infectious diseases